A new study shows how feeding mice a drug called GSM-15606 provided protection against air pollution-related increases in proteins linked to Alzheimer's disease.
A new study shows how feeding mice a drug called GSM-15606 provided protection against air pollution -related increases in proteins linked to Alzheimer's disease.
Air pollution is correlated with systemic inflammation and promotes the formation of amyloid plaques, the clumps of aggregated peptide Aβ42 that form between the brain's nerve cells in Alzheimer's.Alzheimer's & Dementia: The Journal of the Alzheimer's Association The results indicate that GSM-15606 may one day have a role as a preventive measure against Alzheimer's in people living with air pollution, Finch said.
Healthy Aging Pharmacology Dementia Alzheimer's Huntington's Disease Air Quality Pollution Air Pollution
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drugShares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Read more »
Ozempic-Style Drug Slows the Progression of Alzheimer's Disease, Experiment FindsScience and Technology News and Videos
Read more »
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study saysThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop…
Read more »
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study saysThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop…
Read more »
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, EisaiThe committee said Leqembi’s effect on delaying cognitive decline does not outweigh “the risk of serious side effects associated with the…
Read more »
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, EisaiThe committee said Leqembi's effect on delaying cognitive decline does not outweigh 'the risk of serious side effects associated with the medicine.'
Read more »